Case Report: A Case of Gallbladder Carcinosarcoma With Osteoclast-like Multinucleated Giant Cells that Was Associated With RANK‐RANKL Signaling

Niwa, Ayumi; Tomita, Hiroyuki; Watanabe, Naoki; Kiriyama, Shunya; Hara, Akira; Tanaka, Takuji

doi:10.3389/pore.2022.1610134

Cited by 3 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…OGC tumors in other organs, by contrast, are malignant neoplasms. OGC tumors have been found in several other organs including liver, breast, gallbladder, and pancreas (2)(3)(4)(5)(6). Among various histological subtypes of urothelial carcinoma (UC), carcinoma with OGC resembling a giant cell tumor of bone is extremely rare and only a few reports of urothelial carcinoma of the bladder with osteoclast-like giant cells (UCOGCs) have been reported (7)(8)(9)(10)(11).…”

Section: Introductionmentioning

confidence: 99%

Genomic analysis of bladder urothelial carcinoma with osteoclast‑like giant cells: A case report

Kameyama,

Mizutani,

Yamada

et al. 2024

Mol Clin Oncol

View full text Add to dashboard Cite

Urothelial carcinoma of the bladder with osteoclast-like giant cells (UCOGCs) is rare among the subtypes of poorly differentiated urothelial carcinoma. Its clinical significance and optimal treatment are unknown, and few reports on genomic analysis of UCOGCs have been reported. Detailed analysis including genetic analysis for rare type variants of cancer could be a foothold for further research. The present case describes the case of a 75-year-old man who presented with a non-papillary bladder tumor 56 mm in diameter showing gross hematuria and pain on voiding. Following transurethral resection of the bladder tumor, the pathological diagnosis was invasive UCOGCs. Neoadjuvant chemotherapy and radical cystectomy were performed with the resected tumor pathologically diagnosed as invasive UCOGCs, high grade, pT3b, pN1. The present study also analyzed the genomic features using a cancer panel test. The panel test noted six gene alterations ( PIK3CA p.E542K, HRAS p.G13R, ARAF copy number amplification, CDKN2A copy number loss, TP53 p.E285V, ARID1A p.S90Pfs*11) and telomerase reverse transcriptase ( TERT ) promoter variant. Accumulation of knowledge from molecular-based testing is anticipated to determine precise treatment for rare cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Genomic analysis of bladder urothelial carcinoma with osteoclast‑like giant cells: A case report

Kameyama,

Mizutani,

Yamada

et al. 2024

Mol Clin Oncol

View full text Add to dashboard Cite

show abstract

“…Several names have been used in the literature referring to them, including cancer-associated macrophage-like cells (CAMLs) [ 4 ], neoplastic-immune hybrid cells [ 7 ], Polyploid Giant Cancer Cells (PGCC) [ 6 , 8 ], polyaneuploid cells (PACCs) [ 9 ], blastomere-like cancer cells [ 10 ], osteoclast-like cancer cells [ 11 ], circulating giant tumor–macrophages fusion cells [ 12 ], hybrid cells [ 13 ], and pleomorphic cancer cells. It is unclear if different names correspond to different cell characteristics or not.…”

Section: Introductionmentioning

confidence: 99%

Polyploid Giant Cancer Cells Are Frequently Found in the Urine of Prostate Cancer Patients

Castillo¹,

Anract

Delongchamps

et al. 2023

Cancers

View full text Add to dashboard Cite

Prostate cancer is the third cause of cancer-related deaths in men. Its early and reliable diagnosis is still a public health issue, generating many useless prostate biopsies. Prostate cancer cells detected in urine could be the target of a powerful test but they are considered too rare. By using an approach targeting rare cells, we have analyzed urine from 45 patients with prostate cancer and 43 healthy subjects under 50 y.o. We observed a relevant number of giant cells in patients with cancer. Giant cells, named Polyploid Giant Cancer Cells (PGCC), are thought to be involved in tumorigenesis and treatment resistance. We thus performed immune-morphological studies with cancer-related markers such as α-methylacyl-CoA racemase (AMACR), prostate-specific membrane antigen (PSMA), and telomerase reverse transcriptase (TERT) to understand if the giant cells we found are PGCC or other urinary cells. We found PGCC in the urine of 22 patients, including those with early-stage prostate cancer, and one healthy subject. Although these results are preliminary, they provide, for the first time, clinical evidence that prostate cancers release PGCC into the urine. They are expected to stimulate further studies aimed at understanding the role of urinary PGCC and their possible use as a diagnostic tool and therapeutic target.

show abstract

Circulating Polyploid Giant Cancer Cells, a Potential Prognostic Marker in Patients with Carcinoma

Chinen,

Torres,

Calsavara

et al. 2024

IJMS

View full text Add to dashboard Cite

Polyploid Giant Cancer Cells (PGCCs) have been recognized as tumor cells that are resistant to anticancer therapies. However, it remains unclear whether their presence in the bloodstream can be consistently detected and utilized as a clinical marker to guide therapeutic anticancer regimens. To address these questions, we conducted a retrospective study involving 228 patients diagnosed with six different types of carcinomas (colon, gastric, NSCLC, breast, anal canal, kidney), with the majority of them (70%) being non-metastatic. Employing a highly sensitive liquid biopsy approach, ISET®, and cytopathological readout, we isolated and detected circulating PGCCs in the patients’ blood samples. PGCCs were identified in 46 (20.18%) out of 228 patients, including in 14.47% of 152 non-metastatic and 29.85% of 67 metastatic cases. Patients were subsequently monitored for a mean follow up period of 44.74 months (95%CI: 33.39–55.79 months). Remarkably, the presence of circulating PGCCs emerged as a statistically significant indicator of poor overall survival. Our findings suggest that circulating PGCCs hold promise as a reliable prognostic indicator. They underscore the importance of further extensive investigations into the role of circulating PGCCs as a prognostic marker and the development of anti-PGCC therapeutic strategies to improve cancer management and patient survival.

show abstract

Case Report: A Case of Gallbladder Carcinosarcoma With Osteoclast-like Multinucleated Giant Cells that Was Associated With RANK‐RANKL Signaling

Cited by 3 publications

References 31 publications

Genomic analysis of bladder urothelial carcinoma with osteoclast‑like giant cells: A case report

Genomic analysis of bladder urothelial carcinoma with osteoclast‑like giant cells: A case report

Polyploid Giant Cancer Cells Are Frequently Found in the Urine of Prostate Cancer Patients

Circulating Polyploid Giant Cancer Cells, a Potential Prognostic Marker in Patients with Carcinoma

Contact Info

Product

Resources

About